Kathy Mansour Ojjeh Bio, Wiki
Kathy Mansour Ojjeh is best known for being the wife of Mansour Akram Ojjeh, a French Saudi Arabian-born entrepreneur who owned part of TAG, a Luxembourg-based holding company with interests worldwide. Ojjeh was the CEO of TAG, which owns 14.32% of the McLaren Group, assets of which include McLaren Automotive and the McLaren Formula One team since the 1970s and 2000s.
Ojjeh died on the morning of 6 June 2021, at the age of 68.
— Carlos Jimeno (@noticiascarlos) June 6, 2021
Kathy Mansour Ojjeh & Mansour Akram Ojjeh
Kathy lives in a big manor in Switzerland named Le Maison du Lac. She lived with her husband before his death on June 6th, 2021. The couple had one child during their marriage.
Ojjeh was born in 1952 and was the son of Syrian-born Saudi businessman Akram Ojjeh, son-in-law to Mustafa Tlass. His mother was French and he spent much of his childhood in France. He attended schools in the United States, graduating in 1974 with a degree in Business Administration from Menlo College in California.
Mansour Ojjeh had total assets of more than $2 Billion. He was the CEO of TAG Holdings, full structure Techniques d’Avant Garde, a Luxembourg-based speculation organization having interests everywhere in the world.
The TAG Holding organization additionally has more than 14.32% of the resources of McLaren Group which incorporates, McLaren car and F1 groups. He was likewise the previous proprietor of TAG Heuer and Mansour additionally proprietor more than 10% of Asprey and Garrard, a gems organization.
All at F1 are shocked and saddened by the passing of Mansour Ojjeh
Stefano Domenicali: "Mansour was someone with incredible talent, passion and energy and was a giant of our sport. I will miss him greatly and so will the whole F1 community." pic.twitter.com/TWoUMzqpXN
— Formula 1 (@F1) June 6, 2021
The oxygen-driven aerosol inhalation therapy
The oxygen-driven aerosol inhalation therapy with budesonide (suspension) and terbutaline sulfate can be used to treat pediatric asthmatic bronchitis. The study by Bian consisted of 60 pediatric patients diagnosed with asthmatic bronchitis in Xuzhou Children’s Hospital from April 2013 to December 2015.
The participants were randomly divided into two groups. The control group was given conventional dexamethasone drip, and the treatment group was given inhalation of budesonide with terbutaline sulfate; antibiotics were given when needed. The pulmonary functions index of the pediatric patients showed no statistically significant differences among the two groups. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in patients of the two groups improved significantly after treatment (p < 0.05).
The evaluation of aerosol inhalation therapy of budesonide (suspension) with terbutaline sulfate showed a definite curative effect that proves that it is safe to use on pediatric asthmatic bronchitis patients. The approach is superior to the conventional dexamethasone treatment and is worth studying in larger populations for recommending it widely. Terbutaline sulfate causes the expansion of bronchi, affecting epithelial cells of bronchi mucosa. This will assist in moving ions and water into the airway, the cilia reducing sputum secretion while decreasing vascular permeability. The process prevents the release of mediators that cause inflammation.